The biologics used for the treatment of moderate and severe psoriasis are mainly receptor fusion proteins or monoclonal antibodies, and they can be divided into four classes, namely anti-TNFα, anti-IL17, anti-IL-23p40 (also known as anti-IL-12p40), and anti-IL-23p19 (5, 7, 38). Here, IL17A is linked to psoriasis.